Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Multi-Target Approach Using Chemotherapy Drug Combo Shows Potential Across Cancer Types with Jeff Glazier General Oncology TRANSCRIPT
Download PDFOct 13, 2025
Jeff Glazier, CEO of General Oncology, is taking a unique approach to treating cancer by using older chemotherapy drugs with broad action but in novel combinations designed to avoid the incidental toxicity. Their primary drug in trials is GO-4 which is focused on shutting down DNA repair in cancer cells to overcome drug resistance. While testing in patients with stage 4 pancreatic cancer, this approach was designed to combat tumor heterogeneity by targeting fundamental processes like proliferation that are common to all cancer cells within a tumor.
Jeff explains, "We're actually taking a different approach than a lot of companies are. And I would say there are really two approaches because we have two different things on, we have a clinical trial right now where we're using old chemotherapy drugs in a new way, and when you combine them together, you really get just a different result. We're trying to shut down DNA repair and kill cancer cells. But the other really interesting thing, and I think it’s underlying general vision, is chemotherapy drugs long ago had very broad action, and with broad action comes unwanted incidental toxicity. And over the years, it's been huge in the industry, or moving towards specific drugs that target specific things and have less incidental toxicity. The unfortunate side effect is that cancer cells can evolve around a drug if there's too much specificity. So we're taking a pretty novel approach with our business of going after drugs that have broad action, but we found a way, we believe, to do it in a way that doesn't have incidental toxicity."
"I certainly feel that you want to have more than one attack. If you only do one, the cancer cells can evolve around it. The drug resistance approach I was referring to was what we call GO-4 in our clinical trial, and we're altering part of the cancer cells’ fundamental biology that is involved in DNA repair and shutting it down. But we're doing it in more than one way."
#GeneralOncology #PancreaticCancer #CancerAwareness #MetastaticCancer #GO4Therapy #CancerResearch #InnovativeTherapies #DrugDevelopment
